RAF1 and melanoma: An ongoing phase I clinical trial is actively exploring the therapeutic dose of oral pan-RAF inhibitor LXH254 in combination with PDR001 PD-1 monoclonal antibody in patients with advanced solid tumors (including NSCLC, ovarian cancer, and melanoma) with MAPK pathway alterations [283].